Loading
IARC estimates 29,966 new cancer cases and 18,205 cancer deaths in Uganda in 2024; the commonest new cancers are cervix uteri, breast and prostate. This page is assembled automatically from OnCo's data: 7 trials with a site there, 1 institution and 1 person, and says what OnCo does not yet hold.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Cervix uteri | 5,164 | 38.2 | Cervical cancer |
| Breast | 3,308 | 24.2 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Prostate | 2,537 | 36.3 | Prostate cancer |
| Oesophagus | 2,186 | 11.0 | Oesophageal cancer |
| Colorectum | 1,784 | 8.6 | Colorectal cancer |
| Kaposi sarcoma | 1,701 | 4.6 | Kaposi sarcoma |
| Liver and intrahepatic bile ducts | 1,649 | 6.7 | Hepatocellular carcinoma |
| Non-Hodgkin lymphoma | 1,535 | 4.7 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Leukaemia | 957 | 2.9 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Stomach | 914 | 4.5 | Gastric & gastro-oesophageal junction cancer |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Cervix uteri | 3,000 | 23.1 | Cervical cancer |
| Oesophagus | 1,999 | 10.2 | Oesophageal cancer |
| Breast | 1,562 | 12.1 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Prostate | 1,544 | 22.4 | Prostate cancer |
| Liver and intrahepatic bile ducts | 1,438 | 6.1 | Hepatocellular carcinoma |
| Colorectum | 1,016 | 5.2 | Colorectal cancer |
| Stomach | 727 | 3.8 | Gastric & gastro-oesophageal junction cancer |
| Non-Hodgkin lymphoma | 720 | 2.5 | Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma |
| Leukaemia | 655 | 2.2 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Kaposi sarcoma | 637 | 1.8 | Kaposi sarcoma |
| Trial | Lead sponsor | ||||
|---|---|---|---|---|---|
| Phase 3 | Recruiting | Hoffmann-La Roche | 192 | 2026-09-21 | |
| Phase 3 | Active not recruiting | Hoffmann-La Roche | 198 | 2026-10-02 | |
| Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 1 | 2026-09-17 | |
| Phase 3 | Active not recruiting | Hoffmann-La Roche | 238 | 2026-09-03 | |
lidERA NCT04961996 | Phase 3 | Active not recruiting | Hoffmann-La Roche | 622 | 2026-06-17 |
| Phase 3 | Active not recruiting | Hoffmann-La Roche | 171 | 2025-12-31 | |
ACTG A5263/AMC 066 NCT01435018 | Phase 3 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 11 | 2021-10-20 |
Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Uganda, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Uganda is open is on the registry page, under Contacts and Locations.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Uganda is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
A deep dive for Uganda is ranked 38 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.